Jul 31, 2025 It is already midsummer, but if you missed the latest numbers focusing on early-stage healthcare investing, here are some highlights that could be relevant to entrepreneurs and fundraising startups in the deep tech, medtech, and biopharma space. The first quarter of 2025 marked a pivotal moment for the venture capital and healthcare startup landscape. As uncertainty continued to ripple through global financial markets, investors, founders, and analysts closely monitored funding trends, exit prospects, and innovation hotspots. Drawing on the latest data from leading industry reports—including the HSBC Healthcare Annual Report Q1 2025, PitchBook-NVCA Venture Monitor, Carta’s VC Fund Performance Report, and Wilson Sonsini’s Entrepreneurs Report—we break down the most important takeaways for startups, investors, and ecosystem players. Please find the downloadable versions of these reports at the end of this summary “Reference” section.
⚠️ Disclaimer:
This article is for educational and informational purposes only. The views expressed do not constitute medical or financial advice.
The VC Market: Early Signs of Recovery, but Headwinds Remain
Capital Deployment and Fundraising Focus
2025 began with VC activity rebounding from recent lows, though the environment remains bifurcated:
- Deal Value Rebounds, Exit Options Limited: According to PitchBook-NVCA, Q1 2025 saw $91.5 billion in deal value, reaching highs not seen since early 2022, fueled by mega-rounds in AI, biotech, and infrastructure. Despite this, exit channels remain constrained—with just 12 VC-backed IPOs and most M&A deals concentrating on earlier-stage or distressed assets.
- AI & Biotech Dominate Large Rounds: Over 71% of Q1’s VC dollars flowed into AI and machine learning startups, but healthtech and biopharma had robust showings. Healthcare investment grew 30% year-over-year, with biopharma accounting for nearly half of all healthcare VC dollars (HSBC).
- VC Fund Performance—Selective and Patient: Carta’s report on 2,500 US VC funds reveals the majority of vintages (2019-2024) are still waiting for strong liquidity events, with DPI (distributions) lagging and LPs focusing on managers who’ve proven they can return capital under tough conditions.
Valuations and Down Rounds
- Valuations Hold in Early Stage, Later Stages Correct: Seed and Series A median pre-money valuations (~$17M and $49M, respectively, Wilson Sonsini) remained stable or grew. In contrast, Series C and later-stage valuations contracted, reflecting reality checks after frothy 2021-2022 levels.
- Down Rounds Now the Norm: For post-Series A companies, down rounds made up 29% of deals in Q1—a trend that’s held steady for two years. Liquidation preferences and protective investor terms have become more prevalent (Wilson Sonsini).
- SAFE Financings Now Dominant: Pre-Seed SAFEs appeared in 91% of pre-Seed rounds, with a median raise of $700,000, signaling continued appetite for fast, founder-friendly early-stage mechanisms.
Biopharma & Healthtech: Funding Rebounds Amid Scientific Progress
Growth in Mega Rounds and First Financings
- Mega Rounds Are the Story: Biopharma saw a surge in $100M+ private rounds, often involving large syndicates—including VCs, crossovers, and corporates—reflecting a “safety-in-numbers” approach.
- Focus on Platform, Oncology, Metabolic, and Autoimmune: Platform technologies and oncology drew the biggest checks, followed by metabolic and autoimmune innovations. Notably, the majority of new first-financing deals were preclinical or Phase I stage.
Exits: Still a Long Road
- Tough IPO Market: New IPOs for biopharma in Q1 2025 typically underperformed; post-IPO performance for several 2024-2025 listings (e.g., Metsera, Maze Tx, Sionna Tx, Aardvark Tx) showed share prices down sharply from issue price(>-70%!!), a warning sign for new entrants.
- Private M&A Trends: On the M&A front, only five notable VC-backed biopharma deals occurred in Q1, with two achieving $1B+ up-fronts. The median time to exit via M&A stayed just above four years from first venture round.
VC Operations: What Founders and GPs Should Know
Fundraising and LP Sentiment
- Dry Powder and Fund Size Trends: Carta analysis confirms that fund sizes are skewing smaller, as LPs are cautious amid slow distributions. VC fundraising in the US set a pace for the lowest annual total in a decade.
- LPs Demand Distributions: With just 37% of 2019 vintage funds having made any distributions, managers face intense pressure to deliver DPI before raising new funds.
Deal Terms Rein in Risk
- Investor Protection: Series B and later financings more frequently featured pay-to-play and participating liquidation preferences to protect against portfolio downside.
- Convertible Note and SAFE Trends: Convertible notes are now mostly used as post-seed bridge financing; median raise has increased, and maturity periods have shortened as investors look for earlier liquidity.
Outlook: What to Watch in the Second Half of 2025
- IPO and M&A Windows: Market observers expect windows for IPOs and M&A to re-open modestly as macro policy clarity returns, but the “flight to quality” and the concentration of proceeds in a handful of mega-deals will likely persist.
- AI and Biotech Remain Attractive: Both AI and biotech venture activity are likely to outpace other sectors, particularly for companies with differentiated technology or potential to disrupt major indications.
- Preparation Is Key: With long timeframes to exit, smart startups are preparing for both M&A and IPO dual tracks and keeping close tabs on metrics like cash runway, cap table management, and exit strategy flexibility.
References:
https://carta.com/data/vc-fund-performance-q1-2025
https://www.wsgr.com/a/web/vgnKwoeAkUKT6MTc96jYem/entrepreneurs-report-q1-2025.pdf
https://nvca.org/wp-content/uploads/2025/04/Q1-2025-PitchBook-NVCA-Venture-Monitor-19001.pdf
Comments